Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QSI 
QuantumSi Inc (QSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: QSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.77% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 394.19M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 3 | Beta 2.96 | 52 Weeks Range 0.61 - 5.77 | Updated Date 11/5/2025 |
52 Weeks Range 0.61 - 5.77 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.1333 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4527.58% |
Management Effectiveness
Return on Assets (TTM) -27.01% | Return on Equity (TTM) -46.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 108773604 | Price to Sales(TTM) 115.53 |
Enterprise Value 108773604 | Price to Sales(TTM) 115.53 | ||
Enterprise Value to Revenue 31.88 | Enterprise Value to EBITDA 0.63 | Shares Outstanding 194297817 | Shares Floating 164970813 |
Shares Outstanding 194297817 | Shares Floating 164970813 | ||
Percent Insiders 12.44 | Percent Institutions 32.31 |
Upturn AI SWOT
QuantumSi Inc
Company Overview
History and Background
QuantumSi Inc. was founded in 2013 and went public in 2021 via SPAC merger. The company focuses on developing next-generation protein sequencing technology.
Core Business Areas
- Next-Generation Protein Sequencing: Develops and commercializes a platform for protein sequencing using its proprietary Single Molecule Sequencing (SMS) technology. Their core offering is the Platinum system.
Leadership and Structure
Dr. Jonathan Rothberg is the founder and Chairman. The company has a typical corporate structure with a CEO and functional VPs.
Top Products and Market Share
Key Offerings
- Platinum System: A protein sequencing platform using single-molecule detection. Market share data is not readily available as the protein sequencing market is emerging. Competitors include Bruker (BRKR), Thermo Fisher Scientific (TMO), and Pacific Biosciences (PACB), though they use different technologies.
Market Dynamics
Industry Overview
The protein sequencing market is an emerging field with the potential to revolutionize drug discovery, diagnostics, and personalized medicine.
Positioning
QuantumSi aims to be a leader in the protein sequencing market with its unique SMS technology. Competitive advantage relies on accuracy, throughput, and cost-effectiveness of their platform.
Total Addressable Market (TAM)
The estimated TAM is $37 billion. QuantumSi is positioning itself to capture a significant share through the capabilities of its Platinum system to advance novel therapeutics and multiomics.
Upturn SWOT Analysis
Strengths
- Proprietary SMS technology
- Potential for high throughput
- Experienced leadership team
- Early mover advantage in protein sequencing
Weaknesses
- Limited commercial traction
- High cash burn rate
- Need for extensive validation data
- Dependence on single product
Opportunities
- Growing demand for protein sequencing
- Expansion into new applications (diagnostics, drug discovery)
- Partnerships with pharmaceutical companies
- Increased automation and data analysis capabilities
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory hurdles
- Market adoption risks
Competitors and Market Share
Key Competitors
- BRKR
- TMO
- PACB
Competitive Landscape
QuantumSi's advantage lies in its SMS technology, but it faces competition from established companies with broader product portfolios and larger customer bases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to product being relatively new and still in the commercial ramp-up phase.
Future Projections: Future growth depends on adoption of the Platinum system and expansion into new markets. Analyst estimates would be needed for specific projections.
Recent Initiatives: Focusing on commercial expansion, product development, and strategic partnerships.
Summary
QuantumSi Inc. is an early-stage company with innovative protein sequencing technology. Its potential lies in disrupting the market and capturing market share. Its weaknesses include limited commercial traction and dependence on one core product. They need to look out for the financial performance and aggressive competitive companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (where available)
- Yahoo Finance
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Market share estimates are approximate and may not be precise. This is not investment advice. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About QuantumSi Inc
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-10 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.